TABLE 1.
Country | Sequence type(s) | Capsule type(s) | Resistance mechanism(s) | Plasmid replicon type(s) | Formation mechanisms* | References |
China | ST29 (n = 1) | K54 (n = 1) | blaNDM–5 (n = 1) | pvirIncHI1/IncFIB presIncX3 | ∘∘ | Yuan et al., 2019 |
ST1764 (n = 7) ST11 (n = 6) | K64 (n = 7) K47 (n = 4), K64 (n = 2) | blaNDM–1 (n = 7) blaKPC–2 (n = 6) | NA | NA | Liu Z. et al., 2019 | |
ST86 (n = 1) | K2 (n = 1) | blaNDM–1, blaKPC–2 co-carrying (n = 1) | pvirIncHI1/IncFIB presIncFII(K) and presIncN | ∘∘ | Liu Y. et al., 2019 | |
ST11 (n = 12) ST23 (n = 1) ST660 (n = 1) ST1660 (n = 1) | K64 (n = 7), K47 (n = 5) K1 (n = 1) K16 (n = 1) K1 (n = 1) | blaKPC–2 (n = 15) | NA | NA | Xu et al., 2019 | |
ST65 (n = 1) | K2 (n = 1) | blaCTX–M–3, blaCTX–M–14 coharboring | NA | NA | Fu et al., 2019 | |
ST23 (n = 1) | K1 (n = 1) | blaVIM–1 (n = 1) | pvirIncHI1B/IncFIBk presIncA and presIncFII | ∘∘ | Dong et al., 2019 | |
ST23 (n = 1) | K1 (n = 1) | blaNDM–1 (n = 1) | NA | ∘∘ | Liu and Su, 2019 | |
ST25 (n = 16) ST11 (n = 3) ST375 (n = 1) | K2 (n = 16) Non-typeable (n = 3) K2 (n = 1) | blaKPC–2 (n = 10), blaNDM–1 (n = 1), ESBLS (n = 5) blaKPC–2 (n = 3) ESBLS (n = 1) | NA | NA | Li et al., 2019 | |
ST15 (n = 7) | KL112 (n = 7) | blaOXA–232 (n = 7) | pres–OXAColKP3-type pres–CTX IncFII pres–MDRIncFIB pvirIncHI1B/IncFIB | ∘∘ | Shu et al., 2019 | |
ST23 (n = 1) | K1 (n = 1) | blaCTX–M–24 (n = 1) | pvir–CTXM IncHI1B/IncFIB | ∘ | Shen et al., 2019 | |
ST23 (n = 2) ST412 (n = 1) ST660 (n = 1) ST700 (n = 1) | K1 (n = 2) K57 (n = 1) K16 (n = 1) K1 (n = 1) | Undefined (n = 2) PhoQD150G (n = 1) PhoQD150G (n = 1) mcr-1 and PhoQD150G (n = 1) | NA | NA | Lu et al., 2018 | |
ST23 (n = 1) | K1 (n = 1) | blaDHA–1 (n = 1) | pres–DHAIncHI5 pvirIncHI1B/IncFIB | ∘∘ | Xie et al., 2018 | |
ST2922 (n = 1) | K1 (n = 1) | blaDHA and blaCTX–M–14 (n = 1) | presIncR pvirIncFIB/IncHI1B | NA | Xu et al., 2018 | |
ST36 (n = 1) | K62 (n = 1) | blaKPC–2 (n = 1) | press–KPC IncFII pvir IncHI1/IncFIB | ∘∘ | Feng et al., 2018 | |
ST11 (n = 1) | K47 (n = 1) | blaKPC–2 (n = 1) | press–KPCIncR,IncFII, IncNpres–MDR IncA/C2 pvir IncHI1B/IncFIB | ∘∘ | Huang et al., 2018 | |
Unknown (n = 18) | K1 (n = 18) | ESBLS and overexpression of efflux pumps (n = 18) | NA | NA | Lin et al., 2018 | |
ST86 (n = 1) | K2 (n = 1) | blaNDM–1- and blaKPC–2- Coproducing (n = 1) | NA | NA | Wei et al., 2018 | |
ST11 (n = 3) | Unknown (n = 3) | blaKPC–2 or blaNDM–1 (n = 3) | NA | NA | Wong et al., 2018 | |
ST11 (n = 1) | Unknown (n = 1) | tet(A) variant and blaKPC–2 (n = 1) | NA | ∘ | Gu et al., 2018 | |
ST11 (n = 3) | K47 (n = 3) | blaKPC–2 (n = 3) | NA | ∘∘ | Gu et al., 2017 Dong et al., 2018b | |
ST11 (n = 4) | Unknown (n = 4) | tet(A) variant and blaKPC–2 (n = 1) | NA | ∘∘ | Yao et al., 2018 | |
ST11 (n = 16) ST268 (n = 2) ST65 (n = 1) ST692 (n = 1) ST595 (n = 1) | K20(n = 5),non-T(n = 11) K20(n = 1),non-T(n = 1)K2 (n = 1) non-T (n = 1) non-T (n = 1) | blaKPC–2 and blaSHV-11 (n = 16) blaKPC–2 and blaSHV-11 (n = 2) blaKPC–2 and blaSHV-11 (n = 1) blaKPC–2 and blaSHV-11 (n = 1) blaKPC–2 (n = 1) | NA | NA | Zhan et al., 2017 | |
ST23 (n = 2) ST268 (n = 3) ST65 (n = 1) ST17 (n = 1) ST420 (n = 1) ST367 (n = 1) ST1658 (n = 1) ST35 (n = 1) | K1 (n = 2) K1 (n = 1),K20 (n = 2) K2 (n = 1) Non-typeable (n = 1) K20 (n = 1) K1 (n = 1) K2 (n = 1) Non-typeable (n = 1) | SHV-75, CTXM-55, SHV-11, TEM-1, CTX-M-like, SHV-148, CTX-M-14, TEM-53 (n = 11) | NA | NA | Zhang Y.W. et al., 2016 | |
ST86 (n = 7) ST37 (n = 6) ST23 (n = 5) | Unknown | ESBLS (n = 18) | NA | NA | Zhang J. et al., 2016 | |
ST661 (n = 1) | K1 (n = 1) | mcr-1 (n = 1) | NA | NA | Gu et al., 2016 | |
ST14 (n = 1) | K2 (n = 1) | blaNDM–5 (n = 1) | NA | NA | Liu et al., 2016 | |
ST11 (n = 1) | K1 (n = 1) | blaKPC–2 (n = 1) | pvirs–KPCIncFIIk | ∘ | Wei et al., 2016 | |
ST23 (n = 1) ST23 (n = 1) ST1797 (n = 3) |
K1 (n = 1) K1 (n = 1) K1 (n = 3) |
blaKPC–2 (n = 1) blaKPC–2 (n = 1) blaKPC–2 (n = 3) |
pvirs–KPCIncHI1B/IncFIB NA NA |
∘ ∘∘ ∘ |
Zhang R. et al., 2015 Dong et al., 2018a | |
ST65 (n = 1) | K2 (n = 1) | SHV-11,TEM-53-producing ompK35,36 decreased (n = 1) | NA | NA | Zhang Y.W. et al., 2015 | |
ST25 (n = 2) ST65 (n = 5) ST11 (n = 1) | K2 (n = 2) K2 (n = 5) Non-typeable (n = 1) | blaKPC–2 (n = 6) | NA | NA | Yao et al., 2015 | |
Unknown (n = 5) | K1 and K2 (n = 5) | ESBLS (n = 5) | NA | NA | Li et al., 2014 | |
United Kingdom | ST101 (n = 3) ST383 (n = 3) ST147 (n = 4) ST15 (n = 2) ST48 (n = 1) | Unknown | blaOXA-48 and MDR (n = 1), MDR (n = 2) blaOXA-48 (n = 1), blaNDM–5 (n = 2), MDR (n = 1) blaNDM–1 and MDR (n = 2), MDR (n = 2) blaNDM and MDR (n = 1), MDR (n = 1) blaNDM–5 and MDR (n = 1) | pvir–MDR–OXA–48 and (or) -NDM IncFII(K)/IncFIB(K) pres–OXA–48IncL/M pres–NDM–1IncFIB(pQil) pvir–NDM–5 IncFIB(Mar) | ∘ | Turton et al., 2017, 2019 |
Argentina | ST25 (n = 1) | K2 (n = 1) | blaKPC–2 (n = 1) | NA | NA | Cejas et al., 2019 |
Japan | ST23 (n = 1) | K1 (n = 1) | blaIMP-6 (n = 1)qq | pres–IMP–6IncN | ∘∘ | Harada et al., 2019 |
Norway | ST15 (n = 2) | K24 (n = 2) | ESBLS (n = 2) | pvir–CTXM IncFIBK_1/IncFIIK_1 | ∘ | Lam et al., 2019 |
Iran | ST23 (n = 5) | K1 (n = 5) | blaVIM-2 (n = 5) | pres–VIM–2IncN | ∘∘ | Tabrizi et al., 2018 |
United Kingdom | ST23 (n = 1) | K1 (n = 1) | blaNDM–1 (n = 1) | NA | NA | Roulston et al., 2018 |
Italy | ST512 (n = 1) | Unknown (n = 1) | blaKPC-3 (n = 1) | NA | NA | Arena et al., 2017 |
France | ST86 (n = 1) | K2 (n = 1) | blaCTX–M–3 (n = 1) | presIncL/M | NA | Surgers et al., 2016 |
India | ST2318 (n = 1) | Non-typeable (n = 1) | ESBLS (n = 1) | NA | NA | Shankar et al., 2016b |
India | ST11 (n = 1) ST43 (n = 1) ST231 (n = 1) | Unknown | blaOXA–232, blaOXA–181, blaOXA–1, blaNDM–1 | IncFIA IncFIB IncFII IncHI1B Col | NA | Shankar et al., 2016a |
India | ST14 (n = 1) | Unknown (n = 1) | Mutation in OmpK36 (n = 1) | NA | NA | Rafiq et al., 2016 |
United States | ST23 (n = 1) | Unknown (n = 1) | blaKPC–2 (n = 1) | pres–KPCIncFIA | NA | Cejas et al., 2014 |
Brazil | ST11 (n = 7) | Unknown (n = 7) | blaKPC–2 qnrS1 blaCTX-M-2 (n = 7) | press–KPCIncFIIk | NA | Andrade et al., 2014 |
*Single ∘ represents acquiring hybrid plasmid by KPs, double ∘∘ represents acquiring additional plasmid(s), pvir by MDR KPs or pres by hvKPs, respectively.